Literature DB >> 21402130

Low and high affinity dopamine transporter inhibitors block dopamine uptake within 5 sec of intravenous injection.

J T Yorgason1, S R Jones, R A España.   

Abstract

Extensive evidence suggests that the reinforcing effects of cocaine involve inhibition of dopamine transporters (DAT) and subsequent increases in dopamine (DA) levels in the striatum. We have previously reported that cocaine inhibits the DAT within 4-5 s of i.v. injection, matching the temporal profile of the behavioral and subjective effects of cocaine. Intravenous injection of GBR-12909, a high affinity, long-acting DAT inhibitor, also inhibits DA uptake within 5 s. Given that high affinity, long-acting drugs are considered to have relatively low abuse potential, we found it intriguing that GBR-12909 had an onset profile similar to that of cocaine. To further explore the onset kinetics of both low and high affinity DAT inhibitors, we examined the effects of i.v. cocaine (1.5 mg/kg), methylphenidate (1.5 mg/kg), nomifensine (1.5 mg/kg), GBR-12909 (1.5 mg/kg), PTT (0.5 mg/kg), and WF23 (0.5 mg/kg) on electrically-evoked DA release and uptake in the nucleus accumbens core. Results indicate that all of the DAT inhibitors significantly inhibited DA uptake within 5 s of injection. However, the timing of peak uptake inhibition varied greatly between the low and high affinity uptake inhibitors. Uptake inhibition following cocaine, methylphenidate, and nomifensine peaked 30 s following injection. In contrast, peak effects for GBR-12909, PTT, and WF23 occurred between 20 and 60 min following injection. These observations suggest that the initial onset for i.v. DAT inhibitors is extremely rapid and does not appear to be dictated by a drug's affinity.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402130      PMCID: PMC3085557          DOI: 10.1016/j.neuroscience.2011.03.017

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  68 in total

1.  Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys.

Authors:  W L Woolverton; G S Hecht; G E Agoston; J L Katz; A H Newman
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

2.  The rate of intravenous cocaine administration determines susceptibility to sensitization.

Authors:  Anne-Noel Samaha; Yilin Li; Terry E Robinson
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

3.  Determination of release and uptake parameters from electrically evoked dopamine dynamics measured by real-time voltammetry.

Authors:  Q Wu; M E Reith; R M Wightman; K T Kawagoe; P A Garris
Journal:  J Neurosci Methods       Date:  2001-12-15       Impact factor: 2.390

4.  Comparison of dopamine uptake in the basolateral amygdaloid nucleus, caudate-putamen, and nucleus accumbens of the rat.

Authors:  S R Jones; P A Garris; C D Kilts; R M Wightman
Journal:  J Neurochem       Date:  1995-06       Impact factor: 5.372

5.  Self-administration of GBR 12909 on a fixed ratio and progressive ratio schedule in rats.

Authors:  D C Roberts
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  The reinforcing efficacy of the dopamine reuptake inhibitor 2beta-propanoyl-3beta-(4-tolyl)-tropane (PTT) as measured by a progressive-ratio schedule and a choice procedure in rhesus monkeys.

Authors:  Joshua A Lile; Drake Morgan; Anne M Birmingham; Zhixia Wang; William L Woolverton; Huw M L Davies; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

7.  Intravenous drug injection habits: drug users' self-reports versus researchers' perception.

Authors:  G Zernig; S Giacomuzzi; Y Riemer; G Wakonigg; K Sturm; A Saria
Journal:  Pharmacology       Date:  2003-05       Impact factor: 2.547

8.  Novel 2-substituted cocaine analogs: uptake and ligand binding studies at dopamine, serotonin and norepinephrine transport sites in the rat brain.

Authors:  B A Bennett; C H Wichems; C K Hollingsworth; H M Davies; C Thornley; T Sexton; S R Childers
Journal:  J Pharmacol Exp Ther       Date:  1995-03       Impact factor: 4.030

9.  Cocaine: patterns of use, route of administration, and severity of dependence.

Authors:  M Gossop; P Griffiths; B Powis; J Strang
Journal:  Br J Psychiatry       Date:  1994-05       Impact factor: 9.319

Review 10.  Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic--A focus on analogues of benztropine and rimcazole.

Authors:  Amy Hauck Newman; Santosh Kulkarni
Journal:  Med Res Rev       Date:  2002-09       Impact factor: 12.944

View more
  13 in total

1.  Effects of the histamine H₁ receptor antagonist and benztropine analog diphenylpyraline on dopamine uptake, locomotion and reward.

Authors:  Erik B Oleson; Mark J Ferris; Rodrigo A España; Jill Harp; Sara R Jones
Journal:  Eur J Pharmacol       Date:  2012-03-15       Impact factor: 4.432

2.  Modafinil Activates Phasic Dopamine Signaling in Dorsal and Ventral Striata.

Authors:  Martin J Bobak; Matthew W Weber; Melissa A Doellman; Douglas R Schuweiler; Jeana M Athens; Steven A Juliano; Paul A Garris
Journal:  J Pharmacol Exp Ther       Date:  2016-10-12       Impact factor: 4.030

Review 3.  Examining the complex regulation and drug-induced plasticity of dopamine release and uptake using voltammetry in brain slices.

Authors:  Mark J Ferris; Erin S Calipari; Jordan T Yorgason; Sara R Jones
Journal:  ACS Chem Neurosci       Date:  2013-05-06       Impact factor: 4.418

4.  Cholinergic Interneurons Underlie Spontaneous Dopamine Release in Nucleus Accumbens.

Authors:  Jordan T Yorgason; Douglas M Zeppenfeld; John T Williams
Journal:  J Neurosci       Date:  2017-01-23       Impact factor: 6.167

5.  Effects of ( R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell.

Authors:  Jacqueline D Keighron; Juliana C Quarterman; Jianjing Cao; Emily M DeMarco; Mark A Coggiano; Apre Gleaves; Rachel D Slack; Claudio Zanettini; Amy Hauck Newman; Gianluigi Tanda
Journal:  ACS Chem Neurosci       Date:  2019-01-31       Impact factor: 4.418

6.  Daily monitoring of dopamine efflux reveals a short-lasting occlusion of the dopamine agonist properties of d-amphetamine by dopamine transporter blockers GBR 12909 and methylphenidate.

Authors:  Soyon Ahn; Anthony G Phillips
Journal:  ACS Chem Neurosci       Date:  2013-05-03       Impact factor: 4.418

7.  Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: implications for the pathogenesis of free radical-induced neurodegenerative disorders.

Authors:  Ines Peraile; Noelia Granado; Elisa Torres; M Dolores Gutiérrez-López; Rosario Moratalla; M Isabel Colado; Esther O'Shea
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

8.  Methamphetamine increases dopamine release in the nucleus accumbens through calcium-dependent processes.

Authors:  Jordan T Yorgason; David M Hedges; J Daniel Obray; Eun Young Jang; Kyle B Bills; Mark Woodbury; Ben Williams; Mandy J Parsons; Marilou A Andres; Scott C Steffensen
Journal:  Psychopharmacology (Berl)       Date:  2020-01-21       Impact factor: 4.530

9.  Reinforcing Doses of Intravenous Cocaine Produce Only Modest Dopamine Uptake Inhibition.

Authors:  Zachary D Brodnik; Mark J Ferris; Sara R Jones; Rodrigo A España
Journal:  ACS Chem Neurosci       Date:  2016-12-29       Impact factor: 4.418

10.  Hypocretin/Orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by hypocretin receptor 1.

Authors:  Courtney D Prince; Andrew R Rau; Jordan T Yorgason; Rodrigo A España
Journal:  ACS Chem Neurosci       Date:  2014-12-11       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.